Abu Dhabi's Hub71+ Life Sciences hits $463M in startup funding in first year
What's the deal? Hub71+ Life Sciences, Abu Dhabi's specialist health and life sciences ecosystem, marked its first anniversary with a portfolio of 58 startups that have raised $463 million and generated $138 million in revenue. The programme also grew its network to 15 strategic partners, up from 12 at launch.
Who's behind it? The initiative runs in collaboration with the Department of Health — Abu Dhabi, the Emirates Drug Establishment, and the Health, Endurance, Longevity and Medicine (HELM) cluster. It spans biotechnology, medtech, and digital health, from precision medicine to biomanufacturing.
Why now? The milestone lands amid a wider Abu Dhabi push to build out the HELM life-sciences cluster, with recent work across vaccine research, biomanufacturing, medicine logistics, and international research links.
What's on offer? Selected startups receive US$64K in in-kind support services and US$64K in cash in exchange for equity through a SAFE note. High-performers committed to Abu Dhabi can earn a top-up of up to US$64K for additional equity.
What's the endgame? The ecosystem aims to tighten the links between scientific research, clinical development, and commercial application. The expansion to 15 partners — including Johnson & Johnson and Mediclinic Middle EastDealroom has a profile for this one. Try Dealroom → — matters because clinical access and validation often count as much as capital for health startups.
What could go wrong? The headline totals show funding and revenue, not how much growth the programme itself drove. The real test is whether these startups move from pilots to clinical adoption, regulatory approval, and scaled products.
The signal: The figures place Hub71+ Life Sciences among Abu Dhabi's more established startup initiatives and signal an increasingly connected ecosystem — one now betting that clinical validation, not just capital, will set it apart.
Read more: en.aletihad.ae
Image credit: WIPO | OMPI
